NCT02316028View on ClinicalTrials.gov

Phase I:Decitabine by Hepatic Arterial Infusion(HAI) in Unresectable Liver Metastases Colorectal Cancer (CRC)

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

March 31, 2014

Primary Completion Date

December 31, 2016

Study Completion Date

July 31, 2017

Conditions
Liver MetastasisColorectal Cancer
Interventions
DRUG

Decitabine

"administration of decitabine by hepatic arterial infusion~* Accrual of patients and dosing of decitabine will be guided by a traditional 3+3 design using an accelerated titration for the first three dose levels.~* Proposed dose levels:~ 1. 10 mg/m2 per course~ 2. 15 mg/m2 per course~ 3. 20 mg/m2 per course"

Trial Locations (2)

1090

UZ Brussel, Jette

UZ Brussel, Brussels

All Listed Sponsors
collaborator

Janssen, LP

INDUSTRY

lead

Universitair Ziekenhuis Brussel

OTHER

NCT02316028 - Phase I:Decitabine by Hepatic Arterial Infusion(HAI) in Unresectable Liver Metastases Colorectal Cancer (CRC) | Biotech Hunter | Biotech Hunter